Covid-19 will certainly change many aspects of drug approval and the overall regulatory process for biomedical product innovation—first and foremost, new and stronger emphasis on partnership and collaboration across sectors, across disciplines, across borders.

There will be greater clinical-trial innovation in terms of design infrastructure and some of the tools for doing clinical trials. This includes opportunities to integrate digital technologies,…

(Read Full Article Here)